Literature DB >> 29907887

Effect of food on the pharmacokinetics of YH4808, a potassium-competitive acid blocker, after single- and multiple-oral dosing in healthy subjects.

Eunwoo Kim1, Anhye Kim2, Sojeong Yi1, Yu Kyong Kim1, Seong Bok Jang3, Hae Mi Byun3, Seo Hyun Yoon1, Joo-Youn Cho1, In-Jin Jang1, Kyung-Sang Yu1, SeungHwan Lee4,5.   

Abstract

PURPOSE: YH4808 is a potassium-competitive acid blocker, developed for the treatment of acid-related disorders. Two clinical studies in healthy male subjects were conducted to evaluate the effect of food on the pharmacokinetics of YH4808.
METHODS: The first study, a randomized, three-treatment, three-period, crossover study, compared pharmacokinetics of YH4808 (300 mg) after a single dose at fed state with a standard or a high-fat meal to those at fasted state. The second study, a randomized, two-treatment, two-period, crossover study, investigated pharmacokinetics at fasted or fed state with a standard meal after twice daily dose of YH4808 (100 mg) for 7 days. Bloods for pharmacokinetic evaluation were sampled up to 48 h post-dose and 24 h post-dose at steady state, respectively. The pharmacokinetic parameters were estimated by non-compartmental method.
RESULTS: After single dosing, the geometric means of maximum plasma concentration increased by 1.2 and 2.1 times in the fed states with a standard meal and a high-fat meal, respectively, of that in fasted state. Corresponding values of area under the plasma concentration-time curve (AUC) from time 0 to the last measurable time point increased by 1.8 and 2.8 times, respectively. After multiple dosing, the geometric mean for 24-h AUC at steady state slightly increased in fed state by 1.1 times of that in fasted state.
CONCLUSIONS: As fat content of the food increased, the systemic exposure of YH4808 after single dosing increased. However, systemic exposures at steady state after multiple dosing between fasted and fed states were similar. TRIAL REGISTRATION: ClinicalTrials.gov registry no.: NCT01520012.

Entities:  

Keywords:  Food effect; Pharmacokinetics; Potassium competitive acid blocker; YH4808

Mesh:

Substances:

Year:  2018        PMID: 29907887     DOI: 10.1007/s00228-018-2502-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

Review 1.  Improving on PPI-based therapy of GORD.

Authors:  G Sachs
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 2.566

2.  A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.

Authors:  S Yi; H Lee; S B Jang; H M Byun; S H Yoon; J-Y Cho; I-J Jang; K-S Yu
Journal:  Aliment Pharmacol Ther       Date:  2017-05-21       Impact factor: 8.171

Review 3.  Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH.

Authors:  W N Charman; C J Porter; S Mithani; J B Dressman
Journal:  J Pharm Sci       Date:  1997-03       Impact factor: 3.534

4.  Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.

Authors:  P O Katz; J G Hatlebakk; D O Castell
Journal:  Aliment Pharmacol Ther       Date:  2000-06       Impact factor: 8.171

Review 5.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 6.  Gastroesophageal reflux disease.

Authors:  P O Katz
Journal:  J Am Geriatr Soc       Date:  1998-12       Impact factor: 5.562

Review 7.  The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.

Authors:  Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2016-04       Impact factor: 6.447

Review 8.  Peptic ulcer disease.

Authors:  Peter Malfertheiner; Francis K L Chan; Kenneth E L McColl
Journal:  Lancet       Date:  2009-08-13       Impact factor: 79.321

9.  Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?

Authors:  Richard H Hunt; Carmelo Scarpignato
Journal:  Clin Transl Gastroenterol       Date:  2015-10-29       Impact factor: 4.488

Review 10.  New and future drug development for gastroesophageal reflux disease.

Authors:  Carla Maradey-Romero; Ronnie Fass
Journal:  J Neurogastroenterol Motil       Date:  2013-12-30       Impact factor: 4.924

View more
  1 in total

Review 1.  Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker.

Authors:  Hideki Mori; Hidekazu Suzuki
Journal:  J Neurogastroenterol Motil       Date:  2019-01-31       Impact factor: 4.924

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.